Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 13;14(1):166.
doi: 10.1186/s13045-021-01183-2.

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Samuel Bitoun #  1   2 , Julien Henry #  3 , Christelle Vauloup-Fellous  4 , Nicolas Dib  3 , Rakiba Belkhir  3 , Lina Mouna  4 , Candie Joly  5 , Delphine Desjardins  5 , Marie Bitu  5 , Roger Le Grand  5 , Raphaèle Seror  3   5 , Anne-Marie Roque Afonso  4 , Xavier Mariette  3   5
Affiliations
Comment

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Samuel Bitoun et al. J Hematol Oncol. .

Abstract

Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple myeloma (MM) patients (n = 27). Response was analyzed 1 month after the second dose of anti-SARS-CoV-2 BNT162b2 vaccine. Multiple myeloma patients showed diminished levels of Anti-Spike IgG levels compared to controls, but with a high proportion of patients achieving a humoral response (89% vs. 97% in controls). Neutralizing antibodies were present in 74% of patients versus 96% of controls. Patients under current daratumumab treatment had neutralizing activity of anti-SARS-CoV-2 antibodies. Multiple myeloma patients show diminished response to SARS-COV-2 vaccine but with still high response rate. The main potential risk factor of non-response to COVID-19 vaccine was uncontrolled disease under treatment.

Keywords: COVID-19; Daratumumab; Multiple myeloma; Neutralization; SARS-COV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

None of the authors has a relevant conflict of interest.

Figures

Fig. 1
Fig. 1
a Anti-spike IgG levels compared at day 56 after first vaccine injection between multiple myeloma patients and healthy controls. p = 0.0013 using Mann–Whitney test. b Neutralizing activity of anti-SARS-CoV-2 antibodies compared at day 56 after first vaccine injection between multiple myeloma patients and Healthy controls. p = 0.0002 using Mann–Whitney test
See this image and copyright information in PMC

Comment on

References

    1. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021;14(1):81. doi: 10.1186/s13045-021-01090-6. - DOI - PMC - PubMed
    1. Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, et al. Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose. Blood [Internet]. 16 avr 2021 [cité 6 mai 2021]; (blood.2021011904). Disponible sur: 10.1182/blood.2021011904 - PMC - PubMed
    1. Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell Août. 2021;39(8):1028–1030. doi: 10.1016/j.ccell.2021.06.014. - DOI - PMC - PubMed
    1. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173. doi: 10.1182/blood.2021011568. - DOI - PMC - PubMed